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Editor’s key points
† Use of plasma transfusion in
perioperative bleeding and
coagulopathy is limited by
efficacy, volume, preparation,
and serious complications.
† Availability of coagulation factor
concentrates and point-of-care
testing has led to targeted
therapy of haemostatic defects.
† Treatment algorithms appear to
reduce transfusion of allogeneic
blood products through rational
use of factor concentrates.
Summary. Transfusion of allogeneic plasma has been a life-savingmeasure for decades in
patients with severe trauma or suffering from major surgical blood loss. The safety of
allogeneic blood components has improved in terms of pathogen transmission, but
haemostatic efficacy of plasma is hindered by the large volume and time required for
thawing and infusion. Several plasma-derived and recombinant factor concentrates are
clinically available and indicated for targeted replacement of missing coagulation
elements in hereditary disorders of thrombosis and haemostasis. When used
appropriately, factor concentrate therapy can rapidly restore deficient factor(s) without
causing volume overload. The haemostatic defect in perioperative patients is often
multifactorial, and therefore careful clinical judgement and timely coagulation testing
must be exercised before the administration of factor concentrates. In this review, the
rationale for including factor concentrates in perioperative haemostatic management
will be discussed in conjunction with the limitations of plasma transfusion.
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Haemostasis is a natural defence against vascular injury and
haemorrhage.1 It consists of multiple phases involving both
cellular and humoral elements of coagulation (Fig. 1).2 In the
presence of coagulopathy after major trauma and surgery,
haemostasis management becomes a major challenge for
anaesthesiologists and intensivists.3–6 The haemostatic
defect in perioperative patients is oftenmultifactorial, and co-
agulation status can deteriorate rapidly. It is thus important to
address thisproblemwith comprehensive clinical assessments
of coagulopathy, and timely administration of haemostatic
therapy.6–9
Transfusion of plasma and platelets has been themainstay
of haemostatic therapy for many decades. However, the
timing of transfusion is difficult to control, particularly
because blood components and laboratory test results are
often unavailable in a timely fashion. Delayed decision and
administration of transfusion can exacerbate coagulopathy,
and potentially affect clinical outcomes. However, premature
and overzealous use of haemostatic agents can be equally
harmful.10 For a number of hereditary coagulation factor
deficiencies, plasma-derived or recombinant factor concen-
trates are available to replace the deficient factor(s) without
using plasma.11 The US FDA has recently approved a concen-
trate of vitamin K-dependent factors for the management of
bleeding in patients treated with vitamin K antagonists (e.g.
warfarin).12 When managing perioperative bleeding, these
factor concentrates can be more effective than allogeneic
plasma, but inappropriate use can be costly and associated
with worsening haemorrhage or thromboembolic complica-
tions. This article reviews current limitationsof plasmatransfu-
sion, current concepts of coagulationmonitoring, and the roles
of factor concentrates as a perioperative therapy for haemo-
stasis and thrombosis.
Plasma transfusion
In the case of perioperative bleeding, transfusion of fresh-
frozen plasma (FFP; plasma frozen within 8 h) or frozen
plasma (FP24; plasma frozen at 8–24 h after collection) is con-
sidered a life-saving measure. Thawed FFP and FP24 contain
variable, but near-normal, levels of procoagulant proteins,
coagulation inhibitors, albumin, and immunoglobulins.13 14
For example, if fibrinogen is 2 g litre–1 in a unit of plasma
(0.25 litre), it is equivalent to 0.5 g of fibrinogen. However,
plasma fibrinogen increases by only 0.4 g litre21 after 1 litre
of plasma transfusion (median 12.2 ml kg21) in critically ill
patients with bleeding or at risk for bleeding.15 As much as
2.5 litreofplasmatransfusion (median33.5mlkg21) is required
to sufficiently increase fibrinogen by 1 g litre21. This is because
the volume of plasma is added to the circulating blood, and as
such, fibrinogen is distributed in a larger volume of plasma.
Large volumes of plasma transfusion are not tolerated in
patientswith limitedcardiopulmonary reserve,andcanbeasso-
ciated with transfusion-associated circulatory overload.16 17 In
addition, transfusion-related acute lung injury (TRALI) is a po-
tentially lethal complication of plasma transfusion, although
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the incidence has recently declined from1:5000 in 2006 to 1:12
000 in 2009 by preferential use of male donor plasma.18 19
Variable amounts of immunoglobulins, inflammatory cyto-
kines, and cellular debris are also undesirable contents of allo-
geneic plasma.20 21 The volume of plasma transfusion might
not be an issue when it is transfused early in the case of
massive haemorrhage without excess resuscitative fluids
(crystalloids and colloids).4 22 23 In haemorrhagic shock,
plasma transfusion appears to have protective effects on
endothelial glycocalyxand syndecan-1, reducing vascular per-
meability.24 However, plasma transfusion at a fixed ratio with
erythrocytes has not always yielded improved clinical out-
comes, indicating some efficacy and safety limitations.25 26
Theefficacyofplasmatransfusion isaffectednotonlyby the
dose, but also by the timing of intervention. Commonly used
laboratory haemostasis assessment includes prothrombin
time (PT), activatedpartial thromboplastin time (aPTT), fibrino-
gen level (Clauss method), and platelet count. Typical turn-
around time(TAT; time fromspecimencollection to result avail-
ability) for these tests is in the rangeof 30–90min,which is not
optimal in diagnosing coagulopathy or guiding haemostatic
interventions. This is particularly an issue when multiple units
of FFP/FP24 must be thawed according to the laboratory
data, which adds 30–60min of processing time. Delays in hae-
mostatic intervention could have serious consequences in
the case of bleeding involving vital organs (e.g. cerebral
haemorrhage).27 28
Point-of-care coagulation testing
Rapid TAT (,15min) for PT/INR and fibrinogen level29 and pre-
thawed plasma (type AB or A) have been utilized at major
trauma centres in the North America to facilitate timely trans-
fusion,13 but their availabilities are limited elsewhere.30 Alter-
native approaches to conventional laboratory diagnosis and
transfusion of haemostatic components (FFP/FP24, platelets,
and cryoprecipitate) have emerged in Europe since 2005.31
Theprimaryapproach toperioperativediagnosis of coagulopa-
thy ispoint-of-care (POC) testingusing rotational thromboelas-
tometry (ROTEMw) or thrombelastography (TEGw).32 33
Viscoelastic properties of clotting in whole blood assessed by
ROTEMw and TEGw are highly dependent on thrombin-
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Fig1 Haemostatic processes invivoandphase-specific interventions. (A)Haemorrhageoccursaftervascular injury. Extravascular (subendothelial)
collagen and tissue factor are exposed to flowing blood. Transfusion of red blood cells (RBCs) is the initial intervention. Blue, intact vascular wall;
whiteoval, platelets; redcircle, erythrocytes; green,fibrin. (B) Plateletsadhere to thevascular injurysiteby interactingwithvWFviaglycoprotein (GP)
Ib/IX receptors. Mural platelets are activated by collagen and trace thrombin (via extrinsic pathway). They release adenosine-5′-diphosphate and
thromboxane, aggregatingmore platelets in the vicinity. Thus, the primary (haemostatic) plug is established. Platelet transfusion andmeasures to
elevate vWF can augment this process. (C) Activated platelet aggregates serve as a catalytic surface and binding sites for coagulation responses.
Substrates (fibrinogen), pro-enzymatic factors (FII, FIX, FX, FXI, FXIII), and accelerators (FV, FVIII) are congregated (depicted as S-E-A). These
factors can be replaced by either plasma (FFP) or specific factor concentrates (see text for details). Reprinted with permission from Tanaka and
colleagues.2
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mediatedfibrin formationand itspolymerization. Theextentof
fibrin polymerization has become an important endpoint in
perioperative haemostatic management after FIBTEM
became routinely used in ROTEMw.2 34–36 As demonstrated
in the examples of thromboelastometric tracings (Fig. 2),
early amplitudes (A10) or maximum clot firmness (MCF) of
EXTEM and FIBTEM can be used for rapid diagnosis (,15–20
min) of dysfunctional fibrin polymerization, and systemic
fibrinolysis.2 37 Conventional kaolin-TEGw using a-angle is
affected by both platelet count and fibrinogen concentration,38
and functional fibrinogen assay is considered more specific
than TEGw-based detection of hypofibrinogenaemia.39 On the
contrary, fibrin clot firmness cannot be assessed by PT, aPTT,
or fibrinogen level, and prolonged PTand aPTTare poor predic-
tors of bleeding and plasma transfusion.40–42 Large amounts
of plasma transfusion are required to affect clot firmness in
ROTEMw and TEGw,42 43 and fibrinogen-rich components have
recently become the major focus of haemostatic therapy
guided by viscoelastic coagulationmonitors.44
Fibrinogen-rich components
Historical aspects
The prototype of cryoprecipitate dates back to 1956 when a
product called fraction I-O was extracted by Blomback45 from
plasma in the presence of glycine in 6.5% ethanol at 238C.
This fraction was used to treat fibrinogen deficiency, haemo-
philia A (FVIII deficiency), and an unidentified bleeding dis-
order at that time [von Willebrand disease (vWD)]. A method
to produce cryoprecipitate was developed in 1964 by Pool,
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Fig 2 Examples of rotational thromboelastometric tracings. EXTEM reflects the pattern ofwhole blood clotting, which is triggered by tissue factor.
On the FIBTEMtest, fibrin-specific clottingafter tissue factoractivation is demonstratedby inhibiting platelet–fibrin interactionswith cytochalasin
D.2 Normal ranges for EXTEMand FIBTEMare as follows; EXTEM-CT 35–80 s, clot formation time (CFT) 35–160, angle 63–818, A10 50–71mm,MCF
53–72 mm; FIBTEM-A10 7–23 mm, MCF 9–25 mm.33 Pre-treatment: traces obtained from a bleeding patient who incurred major blunt trauma.
Prolonged CTand early clot breakdown are notable on EXTEM. Fibrinolysis is corrected in vitro on APTEM, but CTand amplitude remain abnormal.
Severe hypofibrinogenaemia and fibrin breakdown are also observed on FIBTEM. Post-treatment: after treatment with 2 g of tranexamic acid i.v.,
and transfusion of 20 units cryoprecipitate and 1 units apheresis platelets, CT is nearly normal, andMCF is within normal range on EXTEM. Hyperfi-
brinolysis is no longer detected (EXTEM ¼ APTEM). Fibrin polymerization is improving, but FIBTEM-MCF remains below normal range.
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who discovered that slowly thawed FFP leaves behind a
cold-insoluble precipitate, which contains fibrinogen, FVIII,
von Willebrand factor (vWF), and FXIII.46 47 High volumes of
plasma transfusion in haemophilia A patients were obviated
by the use of Pool’s cryoprecipitate. Although plasma-derived
factor concentrates and recombinant proteins have become
the standard for the treatment of haemophilia A and vWD,
cryoprecipitate has been the mainstay therapy for fibrinogen
replacement in congenital and perioperative fibrinogen
deficiency inNorthAmerica. InEuropeancountrieswherecryo-
precipitate is unavailable, plasma-derived fibrinogen concen-
trate (RiaStapw/Haemocomplettanw; CSL Behring, Marburg,
Germany) has beenapproved for both congenital and acquired
indications.44 48 In the USA, plasma-derived fibrinogen has
been utilized for many years as a key ingredient for topical
fibrin sealants,49 but i.v. injection of fibrinogen concentrate
has only recently been approved by the FDA for the treatment
of congenital afibrinogenaemia or hypofibrinogenaemia.50
Human plasma-derived fibrinogen concentrate
The characteristics of fibrinogen concentrate, cryoprecipitate,
and FFP/FP24 are summarized in Table 1. In contrast to FFP/
FP24, fibrinogen concentrate and cryoprecipitate are fractio-
nated (secondary) components of blood, and can be accepted
by Jehovah’s Witness patients.51 Fibrinogen concentrate is a
lyophilized product, and can be stored at room temperature
(,258C) for up to 30months.50 It can be quickly reconstituted
and administered intravenously because no thawing or blood
type matching is required.52 In contrast to cryoprecipitate or
FFP/FP24, in which fibrinogen content varies, fibrinogen
content is standardized in each vial of fibrinogen concentrate
(900–1300 mg per vial).50 Therefore, fibrinogen concentrate
(1000 mg in 50 ml) should be as effective as cryoprecipitate
(300 mg in 20 ml),53 and superior to FFP/FP24 (250 mg in
100 ml)43 47 for fibrinogen replacement. Testing of donor
plasma for viral pathogens has reduced the risk of viral trans-
mission with cryoprecipitate and plasma-derived factor con-
centrate. Pasteurization (608C for 2 h) and sterile filtrations
are applied to fibrinogen concentrate,54 further reducing the
risk of pathogen transmission.55 The lack of major antibodies
in the concentrate reduces the risk of TRALI.
Perioperative hypofibrinogenaemia and monitoring
fibrinogen level
Hypofibrinogenaemia is linked to bleeding by severalmechan-
isms (Fig. 1). In primary haemostasis, fibrinogen is crucial
in stabilizing vWF-mediated platelet–platelet interactions,
and hypofibrinogenaemia results in the formation of small,
unstable platelet thrombi.56 57 In secondary haemostasis,
fibrinogen-stabilized platelet thrombi provide a catalytic
surface for thrombin generation.1 Platelet-bound fibrinogen
is subsequently converted to fibrin monomer by thrombin,
and fibrin monomers are polymerized by thrombin-activated
FXIII, a transglutaminase.44 Paradoxically, hypofibrinogenae-
mia is associated with thromboembolic complications.58 59
Plausible mechanisms for this include unstable platelet
thrombi,57 reduced sealing of injured vascular wall,60 and sys-
temic release of thrombin and FXa.61 Fibrin is historically re-
ferred to as ‘antithrombin I’ due to these antithrombotic
actions.58 59
Target plasma fibrinogen level is usually set at 1 g litre21 in
congenital fibrinogen deficiency,62 and similar target levels
(0.8–1 g litre21) have been used for acquired deficiency in the
perioperative setting.3 However, higher thresholds (1.5–2 g
litre21) have been recommended in recent European transfu-
sion guidelines.3 63 These changes reflect emerging clinical
data supporting early fibrinogen replacement and higher
Table 1 Characteristics of plasma, cryoprecipitate, and fibrinogen. TRALI, transfusion-related acute lung injury; FFP, fresh-frozen plasma; FP24,
plasma frozen within 24 h; IU, international unit of activity. *Pre-thawed plasma (type AB or A)may be available atmajor trauma centres in North
America. †Pathogen-reduced plasma products are available in North America and European countries
FFP/FP2414 Cryoprecipitate47 Plasma-derived fibrinogen
(RiaStapw/Haemocomplettanw)50
Fibrinogen content per
vial or unit
0.5 g 0.3 g 0.9–1.3 g
Volume per vial or unit 250 ml per unit 20 ml per unit 50 ml per vial
Factor concentration Fibrinogen 2 g litre21 Fibrinogen 15 g litre21 Fibrinogen 20 g litre21
All other factors in variable amounts
(0.5–1.5 IU ml21)
Factor XIII 2.8 IU ml21 Factor XIII 1 IU ml21
Factor VIII 6.3 IU ml21
vWF 8.0 IU ml21
Pre-transfusion
procedures
Thawing* Thawing Mixing with 50 ml diluent
Blood-type compatibility Blood-type compatibility Blood-type free
Storage Frozen Frozen Store at room temp. ,258C
Shelf-life 12 months 12 months 30 months
Pathogen reduction Donor testing† Donor testing Precipitation/adsorption, heat-treated for
viral inactivation
Other considerations Immunoglobulins, cytokines, cell debris Immunoglobulins, cytokines,
cell debris
Minimal immunoglobulins (low TRALI risk)
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target levels after major trauma, perioperative blood loss, and
haemodilution.34 35 48 64
Owing to unpredictable TATof plasmafibrinogen assay, POC
assessment of fibrinogen function is preferred in the surgical
setting; the ROTEMw-based FIBTEM assay is most commonly
utilized.39 65 There are no universally accepted FIBTEM cut-off
values for fibrinogen replacement; target fibrinogen levels
are different depending on the type and extent of vascular
damage (arterial or venous), and levels of other haematologic-
al factors (thrombin generation, red blood cell volume, platelet
function, etc.).60 In most adult cardiac surgical patients, a
target range of 8–10 mm has been used for FIBTEM-MCF (or
A10);48 66–68 this range roughly corresponds to plasmafibrino-
gen of 1.5–2 g litre21.69
There are some practical considerations for the use of fi-
brinogen in surgical patients. First, haemostatic efficacy of fi-
brinogen depends on enzymatic processes, including platelet
activation, endogenous thrombin generation, and activated
FXIII-mediated polymerization. The use of fibrinogen at early
stages of bleeding appears to work well because enzymatic
functions are still intact.34 35 48 64 70 However, fibrinogen re-
placement per semight be insufficient in the case of advanced
or late coagulopathy affecting platelets, proenzymes, and the
fibrinolytic system.35 36 48 60 71 72 In contrast to cryoprecipitate,
FXIII is not effectively replaced after fibrinogen infusion
(Table 1), and separate FXIII infusion is required in some
cases.73 Hyperfibrinolysis cannot be readily diagnosed by
plasma fibrinogen level or PT/aPTT.74 Profibrinolytic state
rendersfibrinogen replacement ineffective, so it shouldbemon-
itored by viscoelastic tests, and antifibrinolytic therapy (tranex-
amic acid or 1-aminocaproic acid) should be considered (Fig. 2).
Dosing of fibrinogen concentrate
In bleeding associated with acquired hypofibrinogenaemia in
adults, plasma fibrinogen is increased by 0.25–0.28 g litre21
(median) per 1 g of fibrinogen administration.75 76 Gorlinger
andcolleagues77 reported thata25mgkg21doseof fibrinogen
in an 80 kgpatient (total 2 g of fibrinogen) results in a 4mm in-
crease in FIBTEM-MCF (or A10). An average fibrinogen dose of
7.6 mg kg21 (0.38 ml kg21 vol) is required to increase
FIBTEM-MCF by 1 mm in adult cardiac surgical patients with
bleeding.52 In contrast, 11–13 ml kg21 of plasma is required
to increase FIBTEM-MCF by 1–1.5 mm.
The dose of fibrinogen concentrate is approximated by the
following formula:
Dose =
[target FIBTEM-MCF (mm)− current
FIBTEM-MCF (mm)] ×weight (kg)
140
For example, if the FIBTEM-MCF were 6 mm in a 70 kg patient
with clinical bleeding, and the target FIBTEM-MCF were
10 mm, the dose of fibrinogen can be calculated to be:
Dose = (10− 6) × 70
140
= 2 g
A similar calculation can be also applied to calculate the
number of pooled units for cryoprecipitate by using a
factor of 5 (assuming 1 g of fibrinogen in 5 pooled units of
cryoprecipitate):
Pooled units of cryoprecipitate = (10− 6) × 70
140
× 5 = 10U
Titrating the dose of fibrinogen concentrate and cryoprecipi-
tate is important in reducingwastage, and potential thrombo-
embolic complications.
Contraindications and adverse reactions
Contraindications to fibrinogen concentrate transfusion
include a previous history of anaphylactic reaction to the con-
centrate,12 andongoing (or suspected) thrombosis, ormyocar-
dial infarction.78 Adverse reactions associated with fibrinogen
concentrate are most commonly fever and headache, but
anaphylactic reactions, deep vein thrombosis, pulmonary em-
bolism,andmyocardial infarctionarepotential risks. Thrombo-
embolic complications directly associated with fibrinogen
concentrate seem to be infrequent according to post-market
surveillance data. Total usage of fibrinogen over 22 yr has
amounted to 1 034 389 g, equivalent to 250 000 doses of 4 g
fibrinogen. The rate of thrombosis was estimated to be 3.48
events per 105 treatments.79 However, actual incidence of
thromboembolic complications could be underreported, and
it is often difficult to prove a causal relationship whenmultiple
haemostatic agents are simultaneously administered.
No case of pathogen transmission has been reported for
fibrinogen concentrate that undergoes pasteurization (608C
for 2 h) and sterile filtrations.55
Prothrombin complex concentrate
Historical aspects
Prothrombin complex concentrates (PCCs) are lyophilized,
human plasma-derived vitamin K-dependent factors contain-
ing FII (prothrombin), FVII, FIX, and FX. PCCs were originally
used for FIX replacement in patients with haemophilia B.80
The potencyof PCC is standardized to FIX content [500 inter-
nationalunit (IU)pervial]. LyophilizedPCCcanbequicklyadmi-
nistered in a low volume (typically, 20–100 ml), and is more
effective than plasma in restoring FIX activity. However,
repeated administration of PCC to maintain FIX activity in
haemophilia Bpatients results in accumulationof prothrombin
and FX due to their long half-lives (40–72 h). Excessive throm-
bin generationmight have occurred in haemophilia B patients
when FIX was added to a supra-physiological level of pro-
thrombin.81 Venous thromboembolic events (VTE), pulmonary
embolism, and disseminated intravascular coagulation (DIC)
have been reported in haemophilia B after repeated doses of
PCC since the 1960s.82 These complications occur far less fre-
quently since the introduction of plasma-derived FIX concen-
trate, and more recently recombinant FIX for the treatment
of haemophilia B.
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PCCs for acute reversal of warfarin
Acute reversal of warfarin using FFP/FP24 is difficult and time-
consuming in thecaseofbleedingcomplicationsoremergency
surgery.27 83 Two commercial PCC products are mainly indi-
cated for the reversal of warfarin anticoagulation. Kcentraw
(referred to as Beriplexw in Europe; CSL Behring) has been re-
cently approved by the FDA, and Octaplexw (Octapharma,
Lachen, Switzerland) is expected to be approved soon. These
and other PCCs have been available in Europe and elsewhere
for some years.84 These PCCs contain therapeutic amounts of
prothrombin, FVII, FIX, and FX (thus four-factor PCC), and
various amounts of protein C, protein S, and protein Z.81 84–86
Other commercially available PCCs are Bebulinw (Baxter, Wes-
tlake Village, CA, USA) and Profilninew (Grifols, Los Angeles, CA,
USA). These are referred to as three-factor PCC, because of low
amounts of FVII relative to FII, FIX, and FX (Table 2).
The use of four-factor PCC is preferred for very high INRs
(.4–5)whenFVII levelsareextremely low(,5%).87 88Recom-
binant activated FVII (rFVIIa; NovoSevenw, Novo Nordisk,
Bagsbaerd, Denmark) has been used in an attempt to normal-
ize INR inwarfarin-treated patients. However, rFVIIa is only ef-
fective in shortening PT/INR, and does not restore thrombin
generation due to the absence of FII and FX.89 90 The use of
rFVIIa is no longer recommended for warfarin reversal91
unless it is used (1–2mg i.v.) in combination with three-factor
PCC.87 88Another typeofPCC isahaemophiliabypassingagent,
factor VIII bypassing agent (FEIBA; Baxter, West Lake Village,
CA, USA), which contains prothrombin, FIX, FX, and activated
FVII (in addition to traces of thrombin, FIXa, and FXa).92
FEIBA has also been used for acute warfarin reversal;93 such
use should be cautioned because of underlying thrombophilic
issues in warfarin-treated patients (see recent reviews regard-
ing the perioperative implications of rFVIIa94 and FEIBA92).
PCCs and FEIBA are considered as a fractionated (secondary)
component of blood, and they can be accepted by Jehovah’s
Witness patients along with recombinant proteins (e.g.
erythropoietin, rFVIIa).51
PCCs alongwith FEIBA and rFVIIa have been suggested as a
potential reversal agent fornoveloral anti-Xaagents (e.g. apix-
aban, edoxaban, rivaroxaban).95 However, the supportive data
are limited to in vitro and animal studies, and in vivo haemo-
static efficacyof PCCs has not been proven in bleeding patients
treated with anti-Xa agents.
Dosing of PCC
Haemostatic efficacy and pharmacological activity of four-
factor PCC compared with FFP have been shown in the multi-
centre prospective randomized study of Kcentraw and FFP in
warfarin-treated adult patients (INR.2.0) undergoing urgent
surgery or invasive procedures (Table 3).12 I.V. vitamin K
(5–10 mg) was administered to both treatment arms. Clinical
haemostasis over 24 h was judged to be effective in 72.4%
(71/98) with Kcentraw (median infused volume 90 ml), and
65.4% (68/104) with FFP transfusion (i.e. PCCwas non-inferior
to FFP).96 The percentage of cases in which INR was reduced
to ≤1.3 after 30 min of intervention was clearly higher with
Kcentraw than with FFP: 62.2% (61/98) vs 9.6% (10/104).
Pharmacological data clearly demonstrate the rapid nor-
malization of vitamin K-dependent factors within 30 min
using PCC, while it takes aminimum of 3 h for plasma transfu-
sion (and vitamin K) to bring procoagulant levels to ≥50%
(Fig. 3).96 Prothrombin (FII) and FX are replenished to 80–
100% activity, and maintained for 24 h by PCC compared
with plasma. These proteins have long half-lives (40–72 h),
and their hepatic production cannot be acutely increased by
vitamin K administration. Plasma levels of FVII and FIX were
increased to 60–80% of normal immediately after PCC, but
the differences from plasma transfusion became smaller
after12hduetovitaminK-stimulatedendogenousproduction.
Similar findings were found for the anticoagulant proteins,
protein C, and protein S (Fig. 3).96
Table2 Prothrombin complexconcentrates. Data indicate relative
contentsof vitaminK-dependent factors fordifferent PCCs. Theper
cent (%) activity of each factor is shown relative to FIX activity
(based on the prescribing information for each product; actual
factor contents may vary for each vial). Manufacturers are as
follows: Kcentraw/Beriplexw (CSL Behring, Marburg, Germany),
Octaplexw (Octapharma, Lachen, Switzerland), Bebulinw (Baxter,
Westlake Village, CA, USA), Profilninew (Grifols, Los Angeles, CA,
USA), and Cofactw (Sanquin, Amsterdam, The Netherlands). Other
PCC products are also available in different countries. Protein C/S,
protein C/protein S; AT, antithrombin; NR, not reported; Yes,
contains therapeutic amounts11
Product
name
FII FVII FIX FX Protein
C/S
Additive
Kcentraw/
Beriplexw
111 57 100 150 Yes Heparin, AT
Octaplexw 98 66 100 96 Yes Heparin
Bebulinw 120 13 100 139 NR Heparin
Profilninew 148 11 100 64 NR No heparin
Cofactw 106 48 100 103 Yes No heparin
Table 3 Treatments for acute warfarin reversal for the Kcentraw study. This table indicates the study protocol from the Kcentraw study.96 IU,
international unit of factor IX; vit K, vitamin K
INR PCC treatment (i.v.) Plasma transfusion (i.v.)
2.0–3.9 PCC 25 IU kg21+vit K 5–10 mg Plasma 10 ml kg21+vit K 5–10 mg
4.0–5.9 PCC 35 IU kg21+vit K 5–10 mg Plasma 12 ml kg21+vit K 5–10 mg
≥6.0 PCC 50 IU kg21+vit K 5–10 mg Plasma 15 ml kg21+vit K 5–10 mg
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140 FII FX
FVII PC
FIX PS
4F-PCC (N = 98)
Plasma (N = 104)
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001 P = 0.165
P = 0.1922
P = 0.7984
P = 0.4468
P = 0.9171
P = 0.7075
P < 0.0001
P < 0.0001P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001 P = 0.0033
P = 0.6108
P = 0.1039
P = 0.1837
P = 0.0037
P = 0.3576
P = 0.3569
P = 0.5569
P = 0.8587
P = 0.4304
P < 0.0001 P < 0.0001 P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001
P < 0.0001 P < 0.0001 P < 0.0001 P = 0.0206
P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
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Fig 3 Coagulation factor levels in warfarin-treated patients who received four-factor PCCor plasma transfusion. Themean plasma coagulation factor levels [% of normal activity (SD)] for FII (pro-
thrombin), FVII, FIX, FX, protein C (PC), and protein S (PS) are shown over 24 h after the injection of four-factor PCC (4F-PCC) or plasma transfusion.96 The elapsed time (h) from the treatment is
indicated on the horizontal axis. Pre, baseline; F, factor. P-values indicate the significant difference in protein levels between the groups.
Coagu
lation
th
erapy
u
sin
g
factorcon
cen
trates
BJAi41
The current indication for four-factor PCC is limited to
warfarin-related bleeding, but various PCCs have been utilized
in acquired, non-warfarin coagulopathy in major trauma and
surgical patients (an off-label indication in North America
and Europe).35 36 48 68 The fibrin polymerization defect is the
primary target of this haemostatic intervention, and the en-
zymatic defect is addressed after hypofibrinogenaemia and fi-
brinolysis (if any) are corrected according to ROTEMw assays.6
35 36 48 68 Prolonged clotting time (CT) on EXTEM over 80–100
s (normal 35–80 s) is used as a cut-off for haemostatic inter-
vention with PCC. Lance and colleagues97 and Tanaka and col-
leagues72 recently demonstrated that prothrombin and FX can
bedecreased to30–40%ofnormalafter perioperativehaemo-
dilution, and bleeding diathesis can continue after fibrinogen
replacement. The rationale for using ROTEMw-based assess-
ment in decisions to transfuse PCC, fibrinogen concentrate,
or both has been prospectively evaluated byWeber and collea-
gues48 compared with centralized laboratory testing in cardiac
surgicalpatients. Four-factor PCC (25 IUkg21)wasadministered
in the presence of prolonged EXTEM-CT (.80 s) and normal
fibrin formation, while plasma or PCC was given if INR .1.4 or
after 4 units of erythrocyteswas transfused (if INRwas unavail-
able) in the cohort evaluated with laboratory tests. The inci-
dence of plasma transfusion was reduced by half (40% vs 80%
P,0.001) using thromboelastometry guidance. The use of PCC
was similar between thromboelastometry and centralized la-
boratory testing (44% vs 52% P¼0.433). In the collective data
analysis from two prospective randomized studies48 67 and
one case–control study68 in which factor concentrates were
part of a transfusion protocol, transfusions of erythrocytes and
plasma were reduced, and the use of PCC and rFVIIa were
effectively controlled by thromboelastometry (Fig. 4). The use
of ROTEMw or TEGw generally results in less plasma transfusion
with or without factor concentrates.98
Although PCC infusion or plasma transfusion guided by
ROTEMw or TEGw is an attractive concept in the management
of vitamin K-dependent factor deficiency, there are some pre-
cautions. First, the CTof ROTEMw and reaction time of TEGw do
nothavethesameoperatingcharacteristicswithPToraPTT.7 99–
101 PT/INR is more standardized than ROTEMw or TEGw for war-
farin reversal using four-factor PCCs.85 86 Kaolin-based reaction
time (.8 min) by TEGw was less predictive of vitamin
K-dependent factor deficiency (≤50% of normal) compared
with an INR .1.5 (positive predictive value, 47% and 84%, re-
spectively).102 Secondly, optimal cut-off values of ROTEMw-CT
andTEGw-reaction timehavenotbeensystematicallyevaluated
or standardized.36 48 68 103 104 Lastly, available haemostatic
products vary among different institutions and countries.
For example, a timely correction of fibrinogen or vitamin
K-dependent factors is difficult when plasma transfusion is the
only available source for these factors.
Contraindications and adverse reactions
Thromboembolic complication is a possible risk of PCCs. In a
recent meta-analysis of 27 studies (1032 patients) including
both three-factor and four-factor PCCs for the reversal of
vitamin K antagonists, the overall incidence of thromboem-
bolic complications was 1.4% (95% CI, 0.8–2.1).105 The use of
PCCs was rarely the direct cause of death, but total mortality
rate was 10.6%, indicating that patients who received PCCs
were often very ill. A low risk of thromboembolic events
(1:31 000) was also described in the pharmacovigilance
study of Beriplexw.106 The lack of major antibodies in PCCs
reduces the risk of TRALI.
The use of PCCs is contraindicated in the case of ongoing
DIC.78 PCCs are known to increase prothrombin and FX levels
(half-lives, 40–72 h) in a dose-dependent manner, and the
balance of procoagulant and anticoagulant proteins can be
shifted towards a hypercoagulable state.
Most PCCs contain subtherapeutic amounts of heparin and
antithrombin (AT), although some contain therapeutic
amountsof proteinC, protein S, andprotein Z.84Grottke andcol-
leagues107 reported thatasingledoseofPCC (50IUkg21;Cofact,
Sanquin, Amsterdam, The Netherlands) was associated with
multiple pulmonary microcapillary thrombi and signs of DIC
(44%) in a porcine model of haemodilution and hepatic injury.
Blood loss was reduced in animals that received the lower
dose (35 IU kg21), or in those that did not develop DIC after a
dose of 50 IU kg21. In DIC animals, haemostasis was not
improved, while plasma AT activity progressively declined to
20%, and thrombin–AT complex levels continued to increase
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Fig 4 Frequencies of allogeneic blood component transfusion and
usage of factor concentrates. Data shown are the percentage of
patients who received transfusions of red blood cell (RBC) concen-
trates, FFP, and platelets in conjunction with fibrinogen concen-
trate, PCC, or recombinant factor VIIa (rFVIIa) in two randomized
controlled studies,48 67 and in a recent matched case–control
trial.68 Numberswithin the columns indicate the numberof patients
receiving transfusion (or infusion)/total number of patients.
Decreased transfusions of RBCs and FFP, and less frequent uses of
PCC and rFVIIa were observed in the thromboelastometry-guided
group compared with the conventional group (*P,0.05 by x2 test).
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over 2 h. In PCC-treated animals with improved haemostasis,
thrombin generation was well regulated as shown in stable AT
activity, and limited increases in thrombin–AT complexes.
Taken together, based on this animal study, there could be an
increased risk of thromboembolic complications when PCCs
are administered in haemodiluted, AT-deficient patients. If AT
deficiency is suspected (e.g. liver dysfunction) or known (e.g.
hereditaryATdeficiency), lowerdosesof PCCsorATreplacement
should be considered, but there is no standardized protocol.
Trace amounts (4–75 units per 10 ml vial) of heparin con-
tained in some PCCs make them contraindicated in patients
with heparin-induced thrombocytopenia (HIT), but no such
case has been reported to date.106 Notably, Profilnine, Cofact,
FEIBA, and rFVIIa do not contain heparin.
ATconcentrate
Physiological roles of AT
AT (formerly AT-III) is a 58 kDa glycoprotein that belongs to a
family of serine protease inhibitors. AT is synthesized in the
liver, and its plasma half-life is 2.5–3.8 days. The primary
targets of AT are serine proteases, thrombin (FIIa), and FXa,
which are being constantly generated (i.e. idling state) in the
circulation. In asymptomatic patients with hereditary ATdefi-
ciency (ATactivity, 40–60% of normal), prothrombin fragment
1.2 levels (amarker of thrombin activation by FXa) are twice as
high as in those in normal subjects (ATactivity, 80–120%). The
risk of VTE is inversely proportional to plasma AT activity
according to the recent population data from Italy.108 After
adjusting for age, gender, body mass index, and hereditary
thrombophilia (6% in patients and 1% in controls), the odds
ratio for VTE in individuals with AT activity 45–60% of normal
was 7.74-fold higher than for those with AT activity .100%.
Similar increases in VTE are also associated with nominal
decreases in protein C and protein S activities. These data indi-
cate that both hereditary and acquired deficiencies of natural
anticoagulants are important risk modifiers of VTE.
TheprevalenceofhereditaryATdeficiency is estimated tobe
one in 2000–5000, but acquired deficiency is more frequently
diagnosed in clinical practice (Table 4). In cardiovascular
patients receiving prolonged heparin infusion (.4–5 days),
plasma AT activity decreases progressively to 50–60% of
normal. Heparin resistance (or insensitivity) is clinically diag-
nosed by increasedheparin dose requirement, and suboptimal
values of aPTT or activated CT (ACT).109 110 Heparin, low-
molecular heparin, and fondaparinux are AT-dependent antic-
oagulants; therefore, ATdeficiencydiminishes their antithrom-
botic efficacies.111 112
Currently, plasma-derived ATconcentrate (Thrombate IIIw;
Grifols)113 and recombinant human AT concentrate (ATrynw;
rEVO Biologics, Framingham, MA, USA)114 are commercially
available (Table 5). Atenativ (Octapharma, Lachen, Switzerland)
andKybernin (CSLBehring) are plasma-derivedATconcentrates
available in Europe.115 RecombinantAT isproduced in transgen-
ic goats carrying a human AT gene, and purified from their
milk.116 Both AT concentrates are indicated for prevention of
VTE in hereditary AT-deficient patients undergoing surgery
and childbirth. Plasma-derived ATconcentrate is also indicated
for treatment of thromboembolic events in hereditary AT defi-
ciency. For any acquired AT deficiency, it is up to the treating
physician to select optimal AT replacement based on clinical
Table 5 Characteristics of AT concentrates. IU, international unit
Plasma-derived AT112 (Thrombate III) Recombinant AT113 (ATryn)
Half-life 3.8 days (per activity assay) 11.6 h (50 IU kg21 dose)
2.5 days (per immunological assay) 17.7 h (100 IU kg21 dose)
AT content per vial 500 IU 1750 IU
Heparin content per vial ,0.004 units per IU of AT ,0.0002 units per IU of AT
Storage Store at room temp ,258C Store refrigerated at 2–88C
Shelf-life 3 yr 3 yr
Loading dose (IU) [(120–baseline AT level)×Wt (kg)]/1.4 Surgical patients: [(120–baseline AT level)×Wt (kg)]/2.3
Peripartum patients: [(120–baseline AT level)×Wt (kg)]/1.3
Maintenance dose 60% of the loading dose repeated (bolus)
every 24 h
Surgical patients (IU h21): [(120–baseline AT level)×Wt (kg)]/10.2
Peripartum patients (IU h21): [(120–baseline AT level)×Wt (kg)]/5.4
(continuous infusion)
Table 4 Acquired ATdeficiencies
Iatrogenic ATdeficiency
Prolonged heparin infusion
L-asparaginase
AT consumption
Surgery/trauma
Extensive cell salvage use
Haemolytic uraemic syndrome
Sepsis/disseminated intravascular coagulation (DIC)
Preeclampsia
Heparin-induced thrombocytopenia
Decreased AT synthesis
Liver dysfunction
Malnutrition
Prematurity/neonates–infants (up to 6 months)
Increased ATexcretion
Nephrotic syndrome
Inflammatory bowel disease
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circumstances. Plasma-derivedAT is a fractionated (secondary)
componentofblood, andcanbeacceptedby Jehovah’sWitness
patients alongwith recombinant AT.51 Available clinical data on
themanagement of acquiredATdeficiencyare discussed below
to further our understanding of AT concentrates and other
therapeutic options.
Perioperative heparin resistance and AT replacement
Cardiovascular surgery and extracorporeal circulatory support
are two clinical situations where heparin insensitivity is fre-
quently encountered. The definition of heparin resistance is
rather arbitrary, and depends on the local practice of heparin
dosing, different cut-off values for aPTTor ACT, and availability
of other diagnostic testing (e.g. preoperative AT activity).110
LowATactivity (≤60%) isobserved inapproximately two-thirds
of heparin-resistant cases in cardiac surgery, and the remain-
der is presumably caused by AT-independent mechanisms
(e.g. thrombocythaemia).117–119 Administering more heparin
in heparin resistance remains a common practice, and total
heparin doses of 800–1200 units kg21 have been reported in
cardiopulmonary bypass (CPB) procedures.109 Potential pro-
blems associated with large doses of heparin in cardiac
surgery include failure to achieve the target ACT, complicated
protamine dose calculations, and an increased risk of heparin
rebound. As a source of AT, plasma transfusion (typically 2
units) has been empirically given in heparin-resistant cardiac
surgical cases.120 Expected recovery of AT is merely 2–3%
per unit of plasma transfusion in an adult, and thus 2 units of
FFP/FP24 would minimally affect plasma ATactivity after hae-
modilution during CPB. Indeed, Avidan and colleagues121
reported that plasma AT activity decreased to 52% on CPB
(baseline AT 74%), and ACTs never improved (,450 s) even
after 2 units of plasma transfusion. Conversely, ATconcentrate
products decrease heparin requirement more reliably in
heparin-resistant cases. Target ACT values have been achieved
in 95% of heparin-resistant CPB cases after plasma-derived
or recombinant AT products.118 121 In placebo-controlled
studies of recombinant AT (75 IU kg21), the intraoperative inci-
dence of plasma transfusion was decreased in the recombinant
AT group comparedwith placebo (19% vs 81%; P,0.001).121 122
Dosing of AT concentrate
The therapeutic dose of ATconcentrate can be calculated from
the baseline and target plasma levels of AT (Table 5). For
example, if baseline AT is 60%, and the target is 80%, the
loading dose of plasma-derived AT for a 70 kg adult is calcu-
lated as:
Dose = (80− 60) × 70
1.4
= 1000 IU
Inmost heparin-resistant cases, plasma-derivedAT is empiric-
ally administered as 500–1000 IU (1–2 vials). Expected AT
increments of 10–20% are generally sufficient to restore
heparin sensitivity in patients with baseline AT activity of 50–
60%.118 123 The initial dose of recombinant AT for peripartum
patients is similar to plasma-derived AT, but the lower initial
dose is used for surgical patients. Continuous infusion is used
to maintain plasma levels of recombinant AT because its half-
life is shorter than that of plasma-derived AT (Table 5). A single
bolus dose of 75 IU kg21 has been tested in clinical trials of re-
combinant AT for the management of heparin resistance. The
mean AT activity was increased from 78% to 130%, and was
maintained at 113% at the end of CPB. Higher AT levels
decreased intraoperative heparin and FFP requirements, but
caused a trend towards increased 24 h postoperative chest
tube drainage. A small increase in postoperative bleeding
(8 ml h21) was also reported by Ranucci and colleagues124 in
CPB patients who received plasma-derived AT to the target
level of 120% before CPB. In their prospective, randomized
study, 100 patients received the median AT dose of 1800 IU
(22.5 IU kg21), while 100 control patients received none.
AT-treated patients had a mean AT activity .90% after CPB,
and received significantly less heparin and protamine compared
withthecontrolgroup.124However,nodifferenceswereobserved
between thegroups in the incidenceofallogeneicbloodcompo-
nent usage, thromboembolic events, low cardiac output, and
in-hospital mortality. Taken together, plasma-derived and re-
combinant AT concentrates are both effective in reducing
heparin and/or plasma transfusion in clinical heparin resistance
in cardiac surgery. However, the optimal target AT levels in
acquired AT deficiency remain elusive, particularly in high-risk
cardiac surgical cases with prolonged CPB (.2.5 h).125 There is
a relative paucity of efficacy data of AT replacement in acquired
deficiency in liver failure,126 127 post-trauma,128 and critical
illness.129 The timing of intervention, co-administration of
heparin, and risk–benefit ratio for haemostasis and thrombosis
should be carefully considered in these settings.127 129
Contraindications and adverse reactions
Plasma-derived and recombinant AT concentrates have rela-
tively few contraindications and side-effects. Recombinant
ATconcentrate is contraindicated in patients with hypersensi-
tivity to goat or goat milk proteins.114 Caution should also be
exercised for recombinant AT, as it is used with a different
dosing regimen in pregnant patients (Table 5). Bleeding com-
plications (haematoma, haemarthrosis, and haemorrhage,
etc.) are rare with either AT concentrate, but such risks might
be increased after an unintended overdose, or with anticoagu-
lation (excess heparin). Both ATconcentrates contain a minis-
cule amount of heparin, but no association of ATconcentrates
with HIT has been reported to date. Heat treatment and sterile
filtrationareappliedtoplasma-derivedand recombinantATcon-
centrates, minimizing the risk of pathogen transmission.113 114
Conclusion
Plasma transfusion has been themainstay haemostatic inter-
vention fordecades for thepreventionand treatmentofhaem-
orrhagic and prothrombotic conditions, often without clearly
defined therapeutic goals.40 41 Its low therapeutic efficacy,
time limitations for thawing and infusion, and potential
hazardshavebeen increasingly recognized, particularly inperi-
operative and critically ill patients.17 Biotherapeutic and
pharmacological factor concentrates have been used for the
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past half-century for treatment of hereditary haematological
disorders.80 Mechanisms of action and safety profiles of
these concentrates have been largely defined within the la-
belled indications through clinical studies, registries, and post-
marketing surveillance.79 105 106 Perioperative use of most
factorconcentrates is still regardedasnon-routineanddifficult
because multifactorial coagulopathy cannot be diagnosed by
standard coagulation tests in a timely fashion, and plasma
transfusion is often empirically administered.9 Early replace-
ment of fibrinogen and correction of hyperfibrinolysis have
becomewidely utilized in Europe after rapid diagnosis of hypo-
fibrinogenaemia and/or fibrinolysis became feasible using
thromboelastometry.3 63 130 The implementation of haemo-
stasis algorithms guided by thromboelastometry appears to
reduce allogeneic blood product usage, and leads to rational
use of factor concentrates.48 63 The use of factor concentrates
is not intended to eradicate plasma transfusion, which has
become increasingly safer.18 19 131 Preferably, factor concen-
trates should be included in patient blood management to
reduce unnecessary plasma and erythrocyte transfusion.132 133
The recent FDA approval of a four-factor PCCwill changeman-
agement of acute warfarin reversal, and reduce the need for
plasma transfusion in the perioperative period.12 In many
countries, most perioperative uses of PCC, fibrinogen, and AT
concentrates are currently considered as ‘off-label’, but
accumulating clinical data indicate that they have important
roles in the management of perioperative haemorrhage, and
prevention of thrombosis.110 131
In contrast to hereditary conditions where a single concen-
trate is indicated, perioperative coagulopathy often requires
multiple haemostatic agents in conjunction with allogeneic
blood components.48 51 72 97 Cumulative clinical data in
Europe demonstrate that a combination therapyof factor con-
centrates and allogeneic blood components is feasible and
more efficient using transfusion algorithms based on POC co-
agulation tests compared with conventional laboratory
methods.48 63 Additional efficacy and safety data are needed
to establish proper perioperative indications, target levels for
specific factor replacement, and cost implications in diverse
perioperative populations (e.g. military casualty, geriatric,
andpaediatric patients). Ongoing clinical studiesonallogeneic
components,134 factor concentrates,135 and synthetic
agents136 137 will clarify optimal transfusion algorithms and
strategies to re-establish the balance of coagulation.136 137
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